RARE

17.20

2.69% 0.45

Pre-mercato: 17.00 -0.20 -1.16%

Ultragenyx Pharmaceutical Inc (RARE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$16.75

Aprire:

$16.73

Volume 24 ore:

2.32M

Relative Volume:

0.77

Capitalizzazione di mercato:

$1.70B

Reddito:

$669.43M

Utile/perdita netta:

$-609.36M

Rapporto P/E:

-2.8169

EPS:

-6.1061

Flusso di cassa netto:

$-507.20M

1 W Prestazione:

+7.84%

1M Prestazione:

+12.27%

6M Prestazione:

-28.87%

1 anno Prestazione:

-50.27%

Intervallo 1D:

$0.00

Intervallo di 1 settimana:

$15.49

$17.35

Portata 52W:

$12.73

$39.89

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Nome

Ultragenyx Pharmaceutical Inc

Settore

Healthcare (1052)

Industria

Biotechnology (595)

Telefono

415-483-8800

Indirizzo

60 LEVERONI COURT, NOVATO, CA

Dipendente

1,371

Cinguettio

Prossima data di guadagno

2026-11-03

Ultimi documenti SEC

RARE's Discussions on Twitter

Compare RARE vs VRTX, MRNA, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RARE Ultragenyx Pharmaceutical Inc	17.20	1.70B	669.43M	-609.36M	-507.20M	-6.1061
VRTX Vertex Pharmaceuticals Inc	529.69	134.26B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	214.16	85.50B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	813.27	83.73B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	891.76	56.08B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	373.36	42.24B	5.76B	514.49M	1.10B	4.4813

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-10-15	Iniziato	UBS	Neutral
2026-09-03	Downgrade	BofA Securities	Buy → Neutral
2026-09-03	Downgrade	Evercore ISI	Outperform → In-line
2026-09-03	Downgrade	JP Morgan	Overweight → Neutral
2026-09-03	Downgrade	Robert W. Baird	Outperform → Neutral
2026-09-03	Downgrade	Wells Fargo	Overweight → Equal Weight
2026-09-03	Downgrade	William Blair	Outperform → Mkt Perform
2026-03-24	Downgrade	Goldman	Buy → Neutral
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-07-28	Ripresa	H.C. Wainwright	Buy
2025-05-28	Iniziato	William Blair	Outperform
2024-06-06	Aggiornamento	Goldman	Neutral → Buy
2024-04-22	Iniziato	RBC Capital Mkts	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-06-06	Aggiornamento	Evercore ISI	In-line → Outperform
2023-04-26	Iniziato	Cantor Fitzgerald	Overweight
2023-01-18	Ripresa	Canaccord Genuity	Buy
2022-12-30	Ripresa	H.C. Wainwright	Buy
2022-11-03	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-10-13	Aggiornamento	Guggenheim	Neutral → Buy
2022-08-01	Downgrade	Evercore ISI	Outperform → In-line
2022-03-16	Aggiornamento	Credit Suisse	Neutral → Outperform
2022-02-11	Aggiornamento	JP Morgan	Neutral → Overweight
2021-09-30	Iniziato	H.C. Wainwright	Buy
2021-08-19	Iniziato	UBS	Sell
2021-07-15	Iniziato	Guggenheim	Neutral
2021-06-29	Aggiornamento	BofA Securities	Neutral → Buy
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-05-06	Aggiornamento	Citigroup	Neutral → Buy
2021-05-06	Aggiornamento	Evercore ISI	In-line → Outperform
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-03-02	Ripresa	Stifel	Buy
2021-02-12	Downgrade	JP Morgan	Overweight → Neutral
2020-12-07	Downgrade	Wedbush	Outperform → Neutral
2020-11-24	Ripresa	Evercore ISI	In-line
2020-11-12	Downgrade	BofA Securities	Buy → Neutral
2019-08-02	Ripresa	Wedbush	Outperform
2019-03-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2019-02-22	Ripresa	Raymond James	Outperform
2019-01-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-11-08	Aggiornamento	Citigroup	Sell → Neutral
2018-09-10	Iniziato	Morgan Stanley	Equal-Weight
2018-06-21	Downgrade	Credit Suisse	Outperform → Neutral
2018-05-11	Aggiornamento	Barclays	Equal Weight → Overweight
2018-05-10	Iniziato	Goldman	Neutral
2018-04-18	Aggiornamento	SunTrust	Hold → Buy
2018-03-22	Ripresa	Piper Jaffray	Overweight
2018-02-21	Reiterato	Stifel	Buy
2018-01-22	Aggiornamento	Evercore ISI	In-line → Outperform
2018-01-18	Iniziato	Credit Suisse	Outperform
2017-12-05	Reiterato	Barclays	Equal Weight
2017-12-04	Aggiornamento	Jefferies	Hold → Buy
2017-09-14	Aggiornamento	Wedbush	Neutral → Outperform

Mostra tutto

Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie

Oct 28, 2026

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research

Oct 28, 2026

GSK (GSK) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research

Oct 28, 2026

Oct 27, 2026

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Zacks Investment Research

Oct 27, 2026

Oct 21, 2026

Form DEF 14A Ultragenyx Pharmaceutical Inc For: 21 October By Investing.com - Investing.com Australia

Oct 21, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $33.65 According to Brokerages - MarketBeat

Oct 21, 2026